Investment Rating - The report assigns a "Buy" rating to the company, with a current price of 5.81 HKD and a fair value of 8.48 HKD [3]. Core Insights - The company achieved a full-year revenue of 1.482 billion RMB in 2025, reflecting a year-over-year growth of 10.1%. The net profit for the same period was 339 million RMB, up 23.8% year-over-year. The growth in profit was attributed to increased overseas revenue and improved gross margins from digital orthopedic products and services [7]. - The gross margin for 2025 was reported at 60.5%, an increase of 0.5 percentage points year-over-year, driven by effective cost control and a higher proportion of revenue from overseas and digital orthopedic products [7]. - The orthopedic surgical robot sales saw a remarkable growth rate exceeding 200% [7]. - The company is implementing a "dual-brand" strategy to enhance its presence in overseas markets, with the K3 intelligent surgical robot receiving regulatory approval in May 2025 and the upgraded K3+ model in January 2026. This strategy aims to provide customized prosthetics and orthopedic surgical robots to international clients [7]. Financial Forecast - The projected revenues for 2026, 2027, and 2028 are 1.679 billion RMB, 1.910 billion RMB, and 2.185 billion RMB, respectively, with growth rates of 13.3%, 13.8%, and 14.4% [7]. - The expected net profits for the same years are 419 million RMB, 524 million RMB, and 643 million RMB, with growth rates of 23.7%, 25.0%, and 22.7% [7]. - The report anticipates a PE ratio of 20X for 2026, leading to a fair value estimate of 8.48 HKD per share [7].

报名：首届全球心血管大会 | 奖项申报 # 财报数据 报名：首届全球骨科大会 | 奖项评选 报名：首届全球眼科大会 | 议程更新 2024年公司 收入达13.46亿元人民币，同比增长23.1% 。公司权益股东应占年度溢利为2.74亿元，同比增长 50.4%。基本每股盈利0.25元，摊薄每股盈利0.24元。拟派发末期股息每股7.2港仙。 毛利达到约8.08亿元，增 长19.8% 。 合作伙伴征集：2025全球手术机器人大会 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 變動百分比 | | | 人民幣千元 | 人民幣千元 | 96 | | 收入 | 1,346,377 | 1,093,862 | 23.1% | | 毛利 | 808.193 | 674.486 | 19.8% | | 年内溢利 | 273,926 | 182,104 | 50.4% | | 本公司權益股東應佔年度溢利 | 273,926 | 182,104 | 50.4% | | 每股盈利 | | | | | 基本 | 人民幣0 ...